Company intelligence / Profile preview

Laurel Rose

San Carlos, California, USA

Ownership: Private
Development stage: Other

Overview

Laurel Rose is a private, clinical-stage biotechnology company focused on developing next-generation small molecule inhibitors for oncology. Founded by the executive team behind Acerta Pharma, the company utilizes its expertise in kinase chemistry to address resistance in B-cell malignancies. The lead candidate, LR-001, is a highly selective Bruton's tyrosine kinase (BTK) inhibitor designed to treat patients who have progressed on existing therapies. Laurel Rose operates with a lean, expert-driven model, focusing on precision medicine and rapid clinical proof-of-concept. The company is headquartered in San Carlos, California, and leverages the deep industry experience of its founders to advance its pipeline.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Laurel Rose.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laurel Rose.

Explore the full profile